Ipatasertib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	21	7	5	50	—	—	2010-03
Malignant Breast Neoplasm	Phase3	Phase 3	8	3	3	19	—	—	Feb 17, 2015
Malignant Prostate Neoplasm	Phase3	Phase 3	2	0	1	5	—	—	Jan 11, 2012
Malignant Ovarian Neoplasm	Phase2	Phase 2	4	1	0	5	—

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PTEN Mutation1
Ipatasertib	Malignant Neoplasm

Clinical trials

Trials with this intervention (50)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 50 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	recruiting	Phase 2	2,900	National Cancer Institute (NCI)NIH	2	Sep 28, 2026	clinicaltrials
NCT05172245	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer	recruiting

PTEN Loss2
Ipatasertib	Malignant Prostate Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID8675 Multicenter, international, phase Ib/II trial evaluating ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Combined blockade with abiraterone and ipatasertib showed… (full text at CIViC) PMID 30037818 · de Bono et al., 2019 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID10876 Phase 3 trial compared ipatasertib plus abiraterone and prednisolone or placebo plus abiraterone and prednisolone for patients with castration resistant prostate cancer. Primary endpoint was radiograp… (full text at CIViC) PMID 34246347 · Sweeney et al., 2021 · Open in CIViC	civic